Section Arrow
ABUS.NASDAQ
- Arbutus Biopharma Corp
Quotes are at least 15-min delayed:2025/11/04 04:58 EST
Pre Market
Last
 --
-- (--)
Bid
4.08
Ask
5.1
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 4.58
-0.15 (-3.17%)
Day High 
4.76 
Prev. Close
4.73 
1-M High
4.945 
Volume 
907.54K 
Bid
4.08
Ask
5.1
Day Low
4.57 
Open
4.7 
1-M Low
4.1 
Market Cap 
906.73M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.53 
20-SMA 4.42 
50-SMA 4.3 
52-W High 5.1 
52-W Low 2.705 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.29/-0.12
Enterprise Value
907.54M
Balance Sheet
Book Value Per Share
0.43
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
14.11M
Operating Revenue Per Share
0.12
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PHIOPhio Pharmaceuticals Corp1.86-0.19-9.27%0.01PE
Pre Market 1.7 -0.16 -8.60%
CRBUCaribou Biosciences2.43+0.01+0.41%-- 
Pre Market 2.42 -0.01 -0.41%
IOVAIovance Biotherapeutics1.95-0.02-1.02%-- 
Pre Market 1.96 +0.01 +0.51%
RXRXRecursion Pharmaceuticals5.44-0.08-1.45%-- 
Pre Market 5.18 -0.26 -4.78%
THARTharimmune Inc.3.2+0.25+8.47%0.03PE
Pre Market 3 -0.2 -6.25%
Quotes are at least 15-min delayed:2025/11/04 04:58 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.